The Immunotherapy Foundation icon, an "if" inside a circle A blue and green "stop" X A DNA symbol in a ring An injection in a ring A pill in a ring A green and blue broken chain link A location icon A dark location icon A telephone icon A dark phone icon An email/letter icon A dark mail icon Facebook icon Facebook icon Twitter icon Twitter icon Instagram icon Instagram icon A hamburger menu A closing X icon A simple caret A systemic icon Bullseye A clock Reduced side-effects Resistance

Making Progress, Every Day.

Keep up with the latest trials and treatments

News & Updates Patient Resources Go T Cells Go!

All Trials & Treatments

Anal Cancer

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors

Trial Identifier: NCT03192345
Phase: 1
Sponsors: Sanofi
Date: Last Updated 6/2017
Regions: US; South; Mary Crowley Cancer Research, Dallas, TX, 75230
Contact: 800-633-1610 ext 1 then NCT# or Contact-US@sanofi.com

To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors, et al.


A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Trial Identifier: NCT03203876
Phase: 1
Sponsors: Bristol-Myers Squibb, Ono Pharmaceuticals
Date: Last updated 8/2017
Regions: Asia; Japan; Local Institution, Kashiwa-shi, Chiba, 2778577 (Site 0001); Local Institution, Kobe, Hyogo, 6500017 (Site 0002)
Contact: Clinical.Trials@bms.com - First line of the email MUST contain NCT # and Site #

The purpose of this study is to determine whether lirilumab in combination with nivolumab or in combination with nivolumab and ipilimumab is safe in the treatment of advanced and/or metastatic solid tumors.


A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Trial Identifier: NCT03192943
Phase: 1
Sponsors: Bristol-Myers Squibb
Date: Last updated 8/2017
Regions: Multi-region; Japan, Local Institution, Chuo-ku, Tokyo, 1040045. Other recruiting sites have contact information.
Contact: Clinical.Trials@bms.com. First line of the email MUST contain NCT # and Site #.

The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors.


The Study of SHR7390 in Combination With SHR-1210 in Patients With Advanced Solid Tumors

Trial Identifier: NCT03182673
Phase: 1
Sponsors: Jiangsu HengRui Medicine Co., Ltd.
Date: Last updated 7/2017
Regions: Asia, China, The Cancer Center, Sun Yat-sen University Guangzhou, Guangdong, 510060
Contact: RuiHua Xu, MD, PhD 86-20-8734-3008 xurh@sysucc.org.cn or Yi Liu, PhD 86-21-6045-3192 ext 822 liuy@shhrp.com.

This aim of study to assess the safety and tolerability of SHR7390 combined with SHR-1210 and to define Dose limiting toxicity(DLT)and the maximum tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors.


Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)

Trial Identifier: NCT03179436
Phase: 1
Sponsors: Merck Sharp & Dohme Corp.
Date: Last updated 7/2017
Regions: US; South; South Texas Accelerated Research Therapeutics, LLC (START) (Site 0001), San Antonio, TX, 78229
Contact: Toll Free Number 1-888-577-8839, Trialsites@merck.com. Refer to this study by its ClinicalTrials.gov identifier.

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of MK-1308 when used in combination with pembrolizumab in participants with advanced solid tumors.


Special Combination of OBP-301 and Pembrolizumab

Trial Identifier: NCT03172819
Phase:  
Sponsors: Toshihiko Doi, National Cancer Center Hospital East; Oncolys BioPharma Inc, Merck Sharp & Dohme Corp.
Date: Last updated 6/2017
Regions: Asia; Japan; National Cancer Center Hospital East; Kashiwa, Chiba
Contact: Dr. Takashi Kojima, +81-4-7133-1111 ext. 91266, OBPem_core@east.ncc.go.jp

This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.


Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Trial Identifier: NCT03172936
Phase: 1
Sponsors: Novartis
Date: Last updated 7/2017
Regions:  
Contact: 1-888-669-6682, Novartis.email@novartis.com. Refer to this study by its ClinicalTrials.gov identifier.

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.


Pembrolizumab in Refractory Metastatic Anal Cancer

Trial Identifier: NCT02919969
Phase: 2
Sponsors: Dana-Farber Cancer Institute; Merck Sharp & Dohme Corp.
Date: Last updated 11/2016
Regions: US; Northeast and Mid-Atlantic; Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute; Boston, MA
Contact: Massachusetts General Hospital: Eunice Kwak, MD, PhD 617-724-4000; Beth Israel Deaconess Medical Center: Benjamin Schlechter, MD, PhD 617-667-3725; Dana Farber Cancer Institute: James Cleary, MD, PhD 617-632-6073

This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: - Pembrolizumab


Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Trial Identifier: NCT02834013
Phase: 2
Sponsors: National Cancer Institute (NCI)
Date: Last updated 9/2017
Regions: Multi-region; See all 555 study sites here
Contact: Use trial site search for specific contact details.

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.


Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Trial Identifier: NCT02628067
Phase: 2
Sponsors: Merck Sharp & Dohme Corp.
Date: Last updated 8/2017
Regions: Multi-region; See all 42 study sites here
Contact: 1-888-577-8839

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.


Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

Trial Identifier: NCT03190811
Phase: 1/2
Sponsors: Capital Medical Unviersity, Duke University
Date: Last updated 6/2017
Regions: Asia; China; Capital Medical University Cancer Center/Beijing Shijitan Hospital, Beijing, 100038
Contact: Jun Ren, MD, PhD 86-10-63926317, renjun9688@yahoo.com

The purpose of this study is to compare the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody alone with anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy in advanced tumor patients. Furthermore, to characterize response to therapy we intent to evaluate the role of cell-free DNA (cfDNA) and immune repertoire based on the next generation sequencing.


Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors

Trial Identifier: NCT02721732
Phase: 2
Sponsors: M.D. Anderson Cancer Center; Merck Sharp & Dohme Corp.
Date: Last updated 6/2017
Regions: US; South; MD Anderson Cancer Center, Houston, TX
Contact: Aung Naing, MD, 713-563-1933

The goal of this clinical research study is to learn if pembrolizumab (also called MK-3475) can help control the disease in patients with advanced cancer.

More Trials image Less Trials image

Anal Cancer (HPV+)

Study of Pomalidomide in Anal Cancer Precursors (SPACE)

Trial Identifier: NCT03113942
Phase: 2
Sponsors: Kirby Institute
Date: Last updated 6/2017
Regions: Australia; Kirby Institute at University of New South Wales, Sydney
Contact: Clinical Trials Coordinator, David Ninham, +61 02 8382 4976, david.ninham@svha.org.au

This is a single centre open label phase II trial to determine the antitumor efficacy of the oral immunomodulatory agent pomalidomide in persistent human papillomavirus (HPV)-associated high grade squamous intra-epithelial lesions (HSIL) in patients with and without human immunodeficiency virus (HIV) infection.


E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers

Trial Identifier: NCT02858310
Phase: 1
Sponsors: National Cancer Institute (NCI)
Date: Last updated 8/2017
Regions: US; Northeast and Mid-Atlantic; National Institutes of Health Clinical Center, Bethesda, MD
Contact: Erin W Ferraro, R.N. (240) 760-6163, erin.ferraro@nih.gov

Researchers will take a person's blood, remove certain white blood cells, and insert genes that make them to target cancer cells that have the E7 protein unique to HPV cancers. The genetically changed cells, called E7 TCR cells, are then given back to the person to fight the cancer. Objective: To determine a safe dose of E7 TCR cells and whether these cells can help patients.


Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer

Trial Identifier: NCT02865135
Phase: 1/2
Sponsors: Dana Farber Cancer Institute, SU2C
Date: Last updated 5/2017
Regions: US; Northeast and Mid-Atlantic; Dana-Farber Cancer Institute, Boston, MA
Contact: Michelle Flynn, RN 617-582-9490, mflynn13@partners.org or Patricia McHugh, RN 617.632.6817, pmchugh@partners.org

This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A*02).


An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)

Trial Identifier: NCT02488759
Phase: 1/2
Sponsors: Bristol-Myers Squibb
Date: Last updated 8/2017
Regions: Multi-region; Recruiting sites have contact information.
Contact: Contact the sites directly: clinical.trials@bms.com; First line of the email MUST contain NCT# and Site #

The purpose of this study to investigate the safety and effectiveness of Nivolumab, and Nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the types of tumors identified.


HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers, HESTIA

Trial Identifier: NCT02379520
Phase: 1
Sponsors: Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine The Methodist Hospital System
Date: 6/2017
Regions: US; South; Houston Methodist Hospital, Houston, TX
Contact: Carlos A. Ramos, MD, 832-824-4817, caramos@bcm.edu or Vicky Torrano, 832-824-7821, vtorrano@bcm.edu

The purpose of this study is to find the biggest dose of HPVSTs (special immune system cells) that is safe, to see how long they last in the body, to learn what the side effects are and to see if the HPVSTs will help people with HPV-associated cancers. (Click trial identifier to read more.)


Hespecta Vaccination in HPV+ Tumors or Malignant Lesions

Trial Identifier: NCT02135419
Phase: 1
Sponsors: Leiden University Medical Center; ISA Pharmaceuticals, Dutch Cancer Society, Top Institute Pharma
Date: Last updated 12/2016
Regions: Western Europe; Netherlands; Leiden University Medical Center, Leiden, 2333 ZA
Contact: H. Gelderblom, Prof.dr. +31715263486, a.j.gelderblom@lumc.nl

A phase I study to establish the highest safe dose that induces HPV16 E6-specific T-cell responses, using the highly promising novel therapeutic vaccine concept named: Hespecta (HPV E Six Peptide Conjugated To Amplivant®) to induce HPV16 E6-specific T-cell responses.

More Trials image Less Trials image

 

Patient Diagram